COPD is a common, progressively disabling disease and a major health burden worldwide. Fourier transform infrared (FTIR) spectroscopy provides for sensitive analysis of complex biological samples. COPD pathogenesis involves quantitative and qualitative changes in sputum biosynthesis. This first study explores whether FTIR can produce distinct spectral profiles of human sputum, and capture differences between COPD and health. Sputum obtained from 15 COPD patients and 15 healthy volunteers was analysed using FTIR spectroscopy; differences in peak positions, height and configuration were identified and measured. All samples gave reproducible characteristic IR absorption spectra. The most relevant regions identified were the amide and glycogen rich regions, showing crucial spectral differences between health and COPD relating to peak position shifts or intensity alteration. These novel preliminary findings support further exploration of FTIR sputum profiling in a clinical study to determine its potential as a practical method for monitoring COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, progressively disabling and complex disease and a major public health problem [Wouters, 2003] ; worldwide, it affects an estimated 600 M people and ranks within the top 5 leading causes of death [Pauwels et al. 2001; WHO 1998 ]. The disease is characterised by partially reversible airflow obstruction driven by in situ inflammatory changes and airway wall remodelling. Consequently COPD patients have a poor quality of life, aggravated by acute distressing flare-ups [Donaldson and Wedzicha, 2006 ]. These infective/inflammatory exacerbations increase with disease severity, occurring on a background of variable but progressive natural decline in the patient's lung function.
There remains a need for routine near-patient sensitive tools to monitor COPD, specifically how to predict which COPD patients are more prone to rapid deterioration in lung function and to increased exacerbations. COPD 'flare-ups' are diagnosed usually on clinical grounds; including a deterioration in specific symptoms (e.g. shortness of breath, coughing and excessive sputum Whilst serial FEV 1 (forced expiratory volume in one second) measurements following bronchodilation have reproducibility and availability [Celli and MacNee, 2004] , they are not predictive of disease progression or outcome. Assessment of COPD has been made by bronchial / lung biopsies and bronchoalveolar lavage [Lofdahl et al. 2006; Saetta et al. 2001] ; whilst greatly advancing our knowledge of COPD status such measures are not amenable to everyday use. Spontaneous and induced sputum analysis has also been performed using a mix of biological technologies [Parr et al. 2006; Maestrelli et al. 2001] . Recent progress with exhaled breath analysis [Montuschi, 2007; Kharitonov and Barnes, 2006; Holz, 2005] looks promising but is limited by high magnitude inter-patient differences in exhaled volatile organic compounds and nitric oxide markers, very low levels of which are not easily detected, so potentially reducing routine clinical value of this biomarker. Thus current methods are in early stage research or at the preclinical trial stage or just not amenable to clinical practice. This leaves a clinical need and challenge in COPD for an effective practical, non-invasive test to enable determination and monitoring of disease status, preferably of sufficient sensitivity for early warning of exacerbations.
Our approach aims to address this need. Fourier transform infrared (FTIR) spectroscopy is a sensitive analytical method which identifies and measures chemical bond vibrations within functional groups in complex biological mixtures by producing an infrared absorption spectrum [Jackson et al. 1997 ]. In FTIR measurements, a particular bond absorbs light electromagnetic (EM) radiation at a specific wavelength e.g. infrared (IR) spectra of proteins will show strong amide I absorption bands at around 1653 cm −1 reflecting the characteristic stretching of C O and C-N and the bending of the N-H bonds. It follows that if a biological sample is examined using EM radiation of many wavelengths within a specified IR range, a distinctive IR molecular 'fingerprint' of said sample can be constructed based on the principle that different chemical bonds absorb different wavelengths of EM radiation. The constructed profile represents the vibrational features of all biochemical components within the analysed sample. Sputum is known to be a complex biological material of different biochemical constituents e.g. lectins, lipids, glycoproteins, proteins, proteoglycans, which can reflect airway health status of the individual producing it. Traditionally it is recognised that COPD onset involves quantitative and qualitative changes in sputum biosynthesis reflecting underlying pathogenesis [Girod et al. 1992] . The present authors hypothesise that FTIR has potential application in the routine, non-invasive analysis of sputum in COPD patients; sputum being a natural expectorated product in over 70% of COPD patients, even during their stable phase.
Whilst FTIR has proven applicability in other disciplines [Ellis and Goodacre, 2006; Mordechai et al. 2004; Kleiner et al. 2002; Uemura et al. 1999; Choo et al. 1993] , to their knowledge the present authors are first to apply FTIR analysis to address the clinical needs of COPD. Accordingly in this preliminary exploratory study, they investigate whether FTIR can produce distinct spectral profiles of human sputum, and capture differences between COPD and health.
Material and methods

Study subjects
The present authors invited consecutive patients with an established diagnosis of moderate to severe COPD [Celli and MacNee, 2004] from their clinic database who fulfilled set criteria including absence of respiratory failure, other respiratory disease and/or active other medical illnesses. 15 patients (mean age 64.9 ± 6.7 years; 11 males, 4 females) were enrolled, with a FEV 1 range from 40 to 65% of predicted value; smoking history ranged from 10-40 pack years with only 2 of the patients recruited being active smokers at the time of the study (Table 1) . 9 patients were daily sputum producers. All patients were receiving β2 agonist therapy. 12/15 patients also took inhaled steroid therapy, whilst 1/15 patients was maintained on low dose oral steroid therapy. 10/15 patients took ipratropium bromide therapy and 4/15 patients aminophylline treatment. Patients 1 and 16 were current smokers, whilst the remainder were ex-smokers (Table 2) .
To enable definition of normal sputum spectra, the present authors required a homogenous group of individuals who had never smoked and did not have any respiratory or co-morbid medical conditions and were not taking any medication. The present authors invited consecutive volunteers from our research database who met these criteria to participate in the study. 15 healthy never-smoking volunteers (mean age 38.5 ± 10.2 years; 4 males, 11 females) were recruited; all had FEV 1 of 100% or greater predicted value (Table 1) . 
Participants who had suffered a COPD exacerbation or an upper respiratory tract infection
Sputum induction
Fresh whole sputum was collected following a standard protocol for sputum induction. This was performed in all subjects using nebulisation of 3% sterile saline solution via an ultrasonic nebuliser (UltraNeb 2000, DeVilbiss, Somerset, USA) with an output of 1.5 ml/min. All subjects inhaled aerosolised saline for 2 consecutive periods of 7 minutes for a total time of 14 minutes, with the FEV 1 monitored at the end of each period for safety reasons; no adverse events occurred.
Sputum analysis
All sputum samples were kept on ice until used and analysed within 30 mins of collection, using a FTIR instrument (Spectrum GX FT-IR, System 2000, Perkin Elmer, UK). Approximately 100 µl of whole sputum was pipetted onto a Barium Flouride polished window and uniformly air dried for 20 mins; this is a necessary step prior to spectroscopic scanning as water absorbs IR radiation and may bias results. The FTIR system had inbuilt software (Version 4.07 provided by the manufacturers) for collecting, viewing and processing spectra over a defined IR range. Spectra were acquired at a resolution of 4.0 cm −1 , scan range of 7800-370 cm −1 and co-addition of 256 scans. Spectra were displayed in terms of absorbance (A), calculated from the reflectanceabsorbance spectra using above software. To minimise problems from unavoidable baseline shifts and to enhance the resolution of superimposed bands, first and second derivatives of the original IR spectral regions were also calculated and compared at a minimum of 37 points for the two study groups; spectra were then deconvoluted to localise relevant peaks otherwise hidden under original broad band contours. Using this method, each sputum sample was measured three times. The wavelength areas of interest dedicated to amide A, II and glycogen regions were analysed in detail by two independent persons (SW and YY).
Statistical Analysis
Differences in peak positions and height between patients with COPD and healthy individuals were identified and quantified utilising above FTIR system software. Statistical analyses were performed using SPSS. Since the data were not normally distributed, comparisons between COPD patients and healthy individuals were made using a non-parametric method, namely the Mann-Whitney test, with a significance level of 0.05.
Results
Fourier transformed IR spectroscopy and data reproducibility
Both COPD and healthy sputum samples gave reproducible characteristic biological IR absorption spectra. In this exploratory study no significant difference in spectra was observed between the current and ex-smokers within the COPD group. The most relevant portion identified within the studied electromagnetic spectrum was the mid-IR region of 4000-800 cm −1 , where we observed consistent vibrational bands within three specific regions, conventionally assigned as amide A, amide II and glycogen rich respectively ( Figure 1 ). Within each of these three regions, gross spectral differences in configuration were revealed between normal and COPD sputa. The coefficient of variability of the differences among the three separate analyses of FTIR sputum profiles in healthy and COPD sputum and the differences between the two groups by both assessors was between 3% and 10%, and altogether, that between the two was <5%.
Amide II region analysis Spectral analysis of absorption and second derivative signals showed that the band of Amide II in healthy sputum was around 1559 cm −1 ; with a consistent pattern of peak shift from this position to around 1561 cm −1 in COPD sputum (Figure 2 ). Analysis of maximum peak position of individual sputa showed a significant difference between patients with COPD and healthy volunteers (Figure 3 , p = 0.0003).
Glycogen rich region analysis
Comparison of the major components of the Glycogen rich region demonstrated a consistent peak position shift from the normal of around 1077 cm −1 towards around 1073 cm −1 in 66% of patients with COPD (10/15) ( Figure 4 ). Analysis of individual maximum peak positions showed a significant difference in peak frequency in this region between the two test groups (Figure 5 , p = 0.0024). Furthermore, separate measurement and analysis of the band intensities at position 1075 cm −1 demonstrated a 3 fold increase in intensity in these same 10 COPD patients compared with normal (p < 0.05) ( Figure 6 ). The remaining 5 COPD patients showed a peak at around 1458 cm −1 ; the significance of this is unclear at the moment and appears to bear no relationship to their demographics.
Amide A region analysis
The amide A region was consistently observed as a band around 3300 cm −1 in both healthy volunteers and COPD patients, with the unexplained exception of 1 control who exhibited the band at 3368 cm −1 . There were no significant differences in maximum peak position wavenumber between the 2 groups (p = 0.52). However, excluding above odd control finding, deconvolution analysis did show that COPD sputa exhibited more peaks over a wider frequency range (3284 to 3315 cm −1 ) compared to normal (3293 to 3306 cm −1 ) (Figure 7) .
Discussion
This preliminary, proof of concept study is the first to explore use of FTIR spectroscopy to analyse biochemical profiles in human sputum and determine airways disease-driven differences. The present authors demonstrate that FTIR can be used to produce distinct sputum spectral profiles. There is potential application for qualitative and quantitative pattern differences between health and COPD sputa relating to peak position shifts, intensies and frequency range at three specific mid-IR regions, characteristically assigned as amide II, Glycogen rich and amide A bands.
The present authors have undertaken some preliminary assignments to the observed specific IR regions using references in established literature on infrared band assignments. Accordingly, the observed shifts within the amide II region from normal to COPD could be attributed to the presence of nitro compounds (NO 2 ), known to be produced by inflammatory cells such as neutrophils, which are recognised to be increased within COPD lungs. Within the glycogen rich area, the changes in peak shift and intensity observed in sputum spectra from 65% of COPD patients may be attributed to CH 2 OH vibrations, C-N vibrations (amines) and the C-O stretching coupled with C-O bending of the C-OH carbohydrates which are frequently found in glycogen rich tissue. DNA also produces a peak in this region. COPD sputum spectra also demonstrated more peaks over a wider frequency range within the amide A region than normals, possibly reflecting COPD-related differences in magnitude and types of proteins (such as enzymes) present. This particular region is also known to be associated with a number of compounds besides proteins such as alkeynes, alcohols, phenols and carboxylic acids. The present authors have also conducted separate preliminary computerised analysis of the maximum band areas across the whole studied IR range to seek other spectral features between two groups. Area differences can be identified at wavenumber positions 529 and 2950 cm −1 . The increase in peak area observed at 529 cm −1 (far-IR region) in COPD sputum spectra could be attributed to aliphatic organohalogen compounds such as bromide, which may be medicinal components in ipratropium bromide inhalers (12 of 15 patients were receiving this therapy). The increase in peak area located at 2950 cm −1 could be attributed to a methyl group reflecting enhanced lipid presence in COPD sputum or alternatively use of methylxanthines in the patients' treatment (however only 4 out of 15 patients were receiving aminophylline). These differential observations in peak area are currently being confirmed. Thus the heterogeneity in the FTIR biochemical fingerprints of COPD sputa are likely to reflect in vivo airway inflammation status with add-on possible effects from treatment; influence from airway bacterial subclinical presence cannot be excluded despite endeavours to ensure patients are clinically infection-free.
The present authors recognise that this first pilot study has a number of possible limitations. First, there is an age mismatch between the normal and COPD groups; however within the practical remit of a small exploratory study, it was not possible to conduct a truly agematched study. This first proof-of-concept investigation required stringent enrolment criteria for the healthy cohort to establish spectral patterns for healthy sputum, especially as there are no a priori published data; it would have been difficult to establish such patterns involving much older subjects who had never smoked or who were completely free of any co-morbid pathology. The present authors are however aware of findings highlighting the need for age matching in studies involving induced sputum, consequent on age-induced differences in sputum key cell types such as neutrophils [Thomas et al. 2004] . Second, the current study did not include a pure smoking 'normal lung function' control group. The present authors accept that smokers do suffer damage to airway bioconstituents e.g. lipids, nucleic acids and proteins, leading to accumulation of excessive protein carbonyls amongst others [Donohue, 2006] ; all of which may bias spectra from smoker COPD patients. However, this first pilot study was not designed to address these issues; having established normal and COPD spectral patterns for human sputum and highlighted the most relevant IR portions of the electromagnetic spectrum, larger longitudinal clinical studies can be informed to address above concerns and evaluate potential of FTIR for clinical COPD practice. Whilst present pilot data did not detect differences in spectra between current and ex-COPD smokers, we are currently conducting studies to clarify add-on effect of smoking habit on FTIR sputum profiles in terms of COPD development and progression. Third, the COPD cohort was characterised as having moderate to severe disease. This was justified as the present study only sought to determine clear-cut differences in sputum spectral patterns from health. Nonetheless, to validate the sensitivity and specificity of FTIR sputum profiling as a future diagnostic biomarker in COPD, the influence/s of evolving disease pathogenesis will need to be explored in a properly stratified patient population to determine whether different disease stages can be distinguished [Celli, 2004] . The present authors did not demonstrate any correlation between identified peak positions and FEV 1 in this small study (data not shown); in any event as FEV 1 might not be the ideal clinical comparator, future studies may elect other appropriate surrogates such as sputum neutrophils, myeloperoxidase and IL-8 levels [Parr et al. 2006 ].
Notwithstanding these limitations, the present findings show that distinct spectral profiles can be established from sputum. These FTIR spectral patterns comprise the quantitative and qualitative changes of all the different constituents of sputum [Girod et al. 1992] , capturing in situ cell-cell-mediator interactions and reflecting the airway health status of the individual producing it. Accordingly, FTIR possesses the requisite versatility, sensitivity and functionality (can be applied to minute sample quantities and feedback is rapid) to be considered as a powerful tool to reveal COPD biomarkers. Much has been published on how COPD onset involves changes in sputum biosynthesis reflecting underlying pathogenetic events; various components of sputum have also been cited as being crucial players in COPD progression and exacerbations [Hill et al. 2000; Nadel, 2000; Chung, 2005; Tetley, 2005; Parr et al. 2006; ] . It follows that changes in FTIR-obtained spectral profiles of serial sputa from any one patient could indicate disease status at a particular time point in the clinical journey and determine progress or predict an exacerbation. As such FTIR has potential merits over other current techniques, which are either unsuitable for self-monitoring or unreliable as they rely on single disease markers inappropriate for a multifactorial process. However, to enable transfer of sputum-related FTIR spectral patterns to a routine diagnostic setting, high requirements in reliability and simplicity of use are a must. Indeed such patterns may rely on small spectral variances between COPD presence and health; thus the present authors stress the importance of future methodical collection of sputa profiles from a cross section of COPD patients to optimize pattern recognition and selection of relevant spectral features with the highest discrimination power. Herein lay the future challenges.
Larger longitudinal studies of COPD patients are likely to produce a 'data cloud' of relevant information; the task will be to tease out the most clinically relevant signatures that can be developed as determinants of disease onset and status. This will require production of portable high performance FTIR systems, incorporating sophisticated computational software, to fit the care needs of respiratory patients. Also, as specific spectral bands may be influenced by the physical state of the sample, development of this novel FTIR protocol will also need to standardise sampling, preparation and data acquisition procedures rigorously in order to minimise spurious effects. This will then establish a panel of reproducible FTIR spectra with clear assignments, which would allow the design of clinically effective and precise algorithms for determining COPD status.
In conclusion, whilst feasibility of FTIR sputum profiling is still in its infancy, the present preliminary findings suggest that FTIR spectroscopy can produce sputum-derived spectral fingerprints which may be compared in same individual over time or possibly used to determine different COPD stages relative to a FTIR reference range for healthy individuals. This now requires validation in a larger clinical study.
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